ALSO NOTED: Canadian regulators warn on impotence drugs; ZARS wins FDA OK; MAP, Elan expand collaboration; and much more...

> Canadian regulators warn of potential vision problems from impotence drugs. Story

> ZARS nabs its first FDA approval for one of its products, the Synera anesthetic patch. Release

> MAP Pharmaceuticals and Elan have expanded their collaboration. Release

> FDA chief, critics clash in House hearings over agency budget. Story

> FDA taps Pfizer to pull Zyvox ad from professional journal. Report

> Swiss manufacturer Lonza sees first-half earnings raised by biopharma unit. Story

> Testosterone patch boosts women's drive but FDA still wants safety data. Report

> AutoGenomics, Targeted Molecular Diagnostics strike development partnership to identify cancer biomarkers to be used for personalized treatments. Release

> Geron starts testing its lead anti-cancer compound with two Phase I/II clinical trials. Release

> Chinese drug maker to supply ingredients to makers of generic anti-AIDS drugs to be distributed by Clinton Foundation in Africa and Asia. Report

And Finally... Giveaway program, advertising guidelines improve drug industry's tarnished image. Feature

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.